Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 19, 2025Clinical Cancer Research

FDA Approval Summary: Blinatumomab for the Treatment of B-cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy

View Full Paper
Ask AI
Bookmark
Share

Authors

CRCara A. RabikSWShu WangRCRitu Chadda

Discussion

Loading...

Member takes

Overview

Randomized trials show improved overall survival with blinatumomab in B-cell precursor acute lymphoblastic leukemia, indicating its role in consolidation therapy.

Key Points

  • Blinatumomab treatment significantly improves overall survival in B-cell precursor acute lymphoblastic leukemia patients during consolidation phase, particularly effective in newly diagnosed cases.
  • In trials, blinatumomab demonstrated an overall survival hazard ratio of 0.42, showing a strong benefit over chemotherapy alone for patients without minimal residual disease.
  • Randomized trials evaluated the efficacy of blinatumomab against standard chemotherapy across various patient groups, revealing its potential significance in treatment outcomes.
  • The findings support using blinatumomab in consolidation therapy, confirming its consistent safety profile across various patient age groups and treatment lines.

Cite This Study

Rabik et al. (2025) studied this question.

synapsesocial.com/papers/68af494dad7bf08b1ead4c7fhttps://doi.org/10.1158/1078-0432.ccr-25-1034
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Data from FDA Approval Summary: Blinatumomab for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy2025
  2. 2Safety and efficacy of consolidation-Phase blinatumomab in newly diagnosed B-cell acute lymphoblastic leukemia : A systematic review and meta-analysis2025
  3. 3Blinatumomab for Replacing Chemotherapy in Pediatric Acute Lymphoblastic Leukemia2026 · 1 citations
  4. 4Children's Oncology Group AALL1331: Phase III Trial of Blinatumomab in Children, Adolescents, and Young Adults With Low-Risk B-Cell ALL in First Relapse2023 · 109 citations
  5. 5Bispecific monoclonal antibody blinatumomab in the first-line therapy of B-lineage acute lymphoblastic leukemia in children and adolescents: interim results of the Russian Ministry of Health approbation protocol2024